M auriac syndrome or glycogenic hepatopathy (GH) is characterized by elevated serum transaminases in patients with type 1 diabetes (T1D) secondary to glycogen deposition in the liver. 1 In the classic description by Mauriac, the patients were children with poorly controlled T1D in the pre-long-term-acting insulin era who presented with growth retardation and cushingoid features. 2 Some recent studies have suggested that the phenotype of patients presenting today may be milder, 3, 4 although there are conflicting observations. 1 GH seems to be most prevalent in patients with poorly controlled T1D, but there have been no comparative studies confirming worse glucose control in these patients compared with T1D without GH. The aim of the current study was to describe the clinical, biochemical, and histopathologic profile of patients with GH and to conduct a matched case-control study to determine whether T1D with GH had more frequent diabetic ketoacidosis (DKA) episodes and elevated hemoglobin A 1c (HbA 1c ) concentrations compared with those without.
Materials and Methods

Study Design
This was a case-control study. Cases were patients with T1D diagnosed with GH and control subjects were patients with T1D without GH. Cases were identified by searching the terms "glycogenic hepatopathy" and "Mauriac syndrome" in electronic medical records at Mayo Clinic, Rochester from January 1, 1998 to January 1, 2014. Age and gender matched control subjects were identified from a Mayo Clinic registry of patients with T1D who had normal liver enzymes. The study was approved by the Mayo Foundation Institutional Review Board.
"Cases" of GH were identified as patients with T1D and a liver biopsy suggestive of glycogenic GH (pathologic overloading of hepatocytes with glycogen); or a clinical diagnosis of GH based on hepatomegaly on clinical examination or hepatic imaging and transaminases elevation >2 times the upper limit of normal. Patients with known chronic liver disease or patients in whom elevated transaminases could be attributed to other causes were excluded.
Study Variables
Demographic, clinical, laboratory, and histopathology variables were abstracted including age at presentation with GH (for cases), age when transaminases were normal (for control subjects), sex, height (cm), weight (kg), body mass index (BMI), percentile height for age, percentile weight for age, and BMI for age. Clinical features comprised history of recurrent episodes of DKA, duration of T1D, age at diagnosis of T1D, symptoms at presentation (abdominal pain, abdominal distention, vomiting), and findings of hepatomegaly and/or splenomegaly on physical examination and/or abdominal imaging. Laboratory findings included HbA 1c (percentage), aspartate transaminase (AST; IU/L), alanine transaminase (IU/L), alkaline phosphatase (IU/ L), g-glutamyltransferase (IU/L), total bilirubin (mg/ dL), direct bilirubin (mg/dL), serum albumin (g/dL), total cholesterol (mg/dL), low-density lipoprotein cholesterol (mg/dL), high-density lipoprotein cholesterol (mg/dL), and triglycerides (mg/dL). Liver biopsy findings including presence of inflammation, mega mitochondria, and fibrosis were also noted. Follow-up transaminase levels were also recorded and were classified as "resolved liver enzymes" or "resolving liver enzymes."
Outcomes
The primary outcome was to compare frequency of recurrent DKA episodes and HbA 1c levels between cases (T1D þ GH) and control subjects (T1D þ normal liver enzymes). Secondary outcomes were to assess differences in clinical presentation, imaging findings, and laboratory investigations between adult (>18 years) and pediatric ( 18 years) patients diagnosed with GH.
Statistical Analysis
Descriptive statistics were calculated using frequencies and percentages for categorical variables and either mean and standard deviation or median and interquartile range for continuous variables. P values were generated using Fisher exact tests for categorical variables and Kruskal-Wallis tests for continuous variables. All statistical analyses were performed using SAS version 9.3 (SAS Institute Inc, Cary, NC).
Results
Thirty-six patients were diagnosed with GH; 20 had liver biopsy and 16 were clinically diagnosed. Hepatomegaly was present in 32 of the 36 patients (88.9%), in 18 (50%) on both clinical examination and imaging, in 10 (27.8%) on imaging only, and in 4 (11.1%) on clinical examination only. Most of the cases were female (28 of 36; 77.8%). Abdominal pain was the most common symptom (23; 63.9%). All patients had poor diabetes control (HbA 1c , 11.2 AE 2.4). Table 1 shows the comparison between patients with T1D with and without GH. In the GH group, a greater frequency of patients had history of recurrent DKA episodes (61% vs 32%; P ¼ .02) and the GH group had higher HbA 1c levels (11.2 AE 2.4 vs 9.0 AE 2.2; P ¼ .003). In pediatric patients with GH, median percentile height for age was 30.5 (range, 1-79) and median percentile weight for age was 64.5 (range, 1-91). In those without GH, median percentile height for age was 54 (range, 4-86) and median percentile weight for age was 77.5 (range, . There was no difference in the frequency of pediatric patients with low (<5) percentile height and weight for age between the 2 groups (16.7% vs 18.2%; P ¼ 1.00). Cases had higher total cholesterol (266.4 AE 95.3 vs 175.0 AE 39.4; P < .0001) and triglyceride levels (291.5 [range, 180-509] vs 88.0 [range, 58-126]; P < .0001) compared with control subjects. There were no differences in BMI, abdominal pain, abdominal distention, vomiting, splenomegaly, total bilirubin, albumin, high-density lipoprotein cholesterol, or low-density lipoprotein cholesterol between the 2 groups.
Patients With Type 1 Diabetes With and Without Glycogenic Hepatopathy
Adult and Pediatric Patients With Glycogenic Hepatopathy
There were 24 adult and 12 pediatric patients with GH (Table 2) . Adults had longer duration of diabetes (13.3 AE 5.8 vs 8.7 AE 3.6; P ¼ .02), higher AST levels (312.5 [range, 245.5-775] vs 157 [range, 104-267]; P ¼ .02), and lower serum albumin levels (3.7 AE 0.5 vs 4.3 AE 0.4; P ¼ .008) than pediatric patients. There was no difference in sex, BMI, abdominal pain, abdominal distention, vomiting, splenomegaly, hepatomegaly, history of recurrent DKA, HbA 1c , alanine transaminase, alkaline phosphatase, g-glutamyltransferase, total bilirubin, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, or triglycerides between the 2 groups.
Clinical Versus Histopathologic Diagnosis of Glycogenic Hepatopathy
The only difference found in the clinical versus histopathologically diagnosed GH cases was in AST levels, which were greater in biopsy proven than in clinically diagnosed cases (301 [range, 245.5-775] vs 150 [range, 69-465.5]; P ¼ .02) ( Table 3 ). Among those with biopsy-confirmed GH, 3 (15%) patients had mega mitochondria observed on histopathology.
Follow-up
Median duration of follow-up was 8 months (range, 1-72) with data available for 21 of the 36 patients. For 18 of the patients the transaminases eventually normalized; in the other 3 patients they were trending down on follow-up. The decrease in transaminases was associated with improvement in glycemic control. None of the patients developed any apparent long-term adverse liver outcomes.
Discussion
This study constitutes the largest series of patients with T1D and GH. The typical clinical presentation was abdominal pain, hepatomegaly, recurrent DKA, elevated HbA 1c levels, and hypercholesterolemia. Growth retardation was infrequently seen in pediatric patients with GH. When compared with patients with T1D with normal liver enzymes, patients with GH more frequently had recurrent DKA and elevated HbA 1c levels. Adult patients with GH had higher AST levels and lower albumin levels compared with pediatric patients. On follow-up, patients had fluctuating liver enzymes, which eventually normalized in most cases.
GH, or Mauriac syndrome, was described by Pierre Mauriac in patients with T1D as hepatomegaly and elevated liver function tests caused by glycogen accumulation in hepatocytes. 2, 5 The term "glycogenic hepatopathy" was recently coined by Torbenson et al 4 to describe this condition. Hepatic glycogenosis occurs secondary to a combination of 2 main factors: elevated glucose levels and elevated insulin levels. Glucose diffuses into hepatocytes and is converted to glucose-6-phosphate by the enzyme glucokinase. Glucose-6-phosphate is converted to glycogen by the enzyme glycogen synthase. Glycogen synthase exists in an active dephosphorylated form and an inactive phosphorylated form. The active dephosphorylated form of glycogen synthase is produced by the action of a phosphatase enzyme, which is stimulated by elevated glucose and insulin levels. Glycogen is mobilized by glycogen phosphorylase typically in the postabsorptive state. Thus, mechanistically, elevated glucose and insulin levels and decreased glycogen phosphorylase activity in the hepatocyte could lead to deposition of glycogen in hepatocytes (Figure 1) .
DKA can be considered as a surrogate marker for poor glycemic control with elevated insulin and glucose levels in T1D. Thus, patients with a history of DKA can be expected to have a higher risk of developing GH. An autopsy study evaluating the glycogen content in the liver of patients dying from DKA showed significantly more glycogen deposition in the liver compared with the livers of persons dying from natural causes. 6 In one of the largest series of GH published by Marble 5 in 1938, nearly 70% of patients with suspected GH had a history of severe DKA. In comparison, a more recent study showed lower rates of frequent DKA of about 30%. 4 However, none of the previous studies compared the rate of DKA with that in T1D without GH. Our current study showed a higher frequency of DKA episodes in patients with GH compared with T1D with normal transaminases. In addition, patients with GH also had greater HbA 1c levels than control subjects. This suggests that poor glycemic control may be associated with the glycogen accumulation seen in GH.
There has been a change in clinical presentation of GH over the last century. In the classic description by Mauriac in 1931, the patient was a 10 year old with poorly controlled T1D with protuberant abdomen, liver enlargement, dwarfism, delayed puberty, cushingoid features, and hypercholesterolemia. 2 In a subsequent large series by Marble, 5 60 children with diabetes and hepatomegaly were reported of whom nearly half were dwarfs. Cushingoid features were frequently seen in earlier reports of GH in the era before the availability of long-acting insulin, purportedly secondary to prolonged hypercortisolism during periods of hypoglycemia. 2, 7 Such findings are infrequently observed today because of use of long-acting insulin and probably the decreased frequency of hypoglycemic events in this patient cohort. As described in a more recent study by Torbenson et al, 4 only 1 of the 5 pediatric patients with GH exhibited classic features of Mauriac syndrome. In another study, none of the 3 patients with GH had such features. 8 In contrast, a recent large study from the United Kingdom showed that overall these patients appeared to be lighter and shorter than UK reference data. 1 However, the authors did not describe what percentage of patients presented with "classic Mauriac" features. Our findings are similar to those of Torbenson et al 4 and Olsson et al, 3 because only 2 of the 12 pediatric patients had growth retardation and cushingoid features. Thus, it seems that currently pediatric patients appear to present with a milder phenotype compared with the initial descriptions of this syndrome.
More recently, GH has been described in young adults with T1D.
3,4,9 Interestingly, two-thirds of the patients in our study were T1D adults presenting with transaminase elevations. Chatila and West 9 compared 8 adults with GH with 3 pediatric patients and found no differences in presentation. By contrast, adult patients with GH in our study had higher AST and lower albumin levels than pediatric cases. In all patients with elevated aminotransferase levels, tests for chronic liver disease were negative. Therefore, high index of suspicion for GH and negative testing for chronic liver disease were criteria for GH for our cohort of patients. Interestingly, we observed higher levels of AST than alanine transaminase in our study; this has not been reported in prior studies. Further studies are warranted to investigate the relevance if any and the mechanistic basis for this observation.
In people with diabetes, hepatomegaly can occur secondary to fat or glycogen deposition. Although, fatty liver is generally seen in obese adults with type 2 diabetes, it is infrequently reported in liver biopsies from T1D with GH. In a study by Chatila and West, 9 moderate steatosis was seen in 25% of biopsies with GH, but none had steatohepatitis. Torbenson et al 4 noted mild steatosis in 14%, mild steatohepatitis in 7%, and mild fibrosis in 14% of cases with GH. In contrast, Fitzpatrick et al 1 observed steatohepatitis in 42% and fibrosis in 74% of these patients. Interestingly, 6% of cases in that study had bridging fibrosis. By comparison, in our study 15% of GH cases had mild inflammation and 10% had mild fibrosis. None of the patients had bridging fibrosis. On follow-up, most patients had fluctuation of the liver enzymes, which eventually normalized in most of the patients as glycemic control improved. None of the patients developed long-term sequelae of liver disease secondary to glycogen accumulation.
In a previous study by Taskinen, 10 glycemic control improved lipid values, with the cholesterol concentration decreasing by 0.1 mM (3.87 mg/dL; 2.2%) and the plasma triglyceride level decreasing by 0.08 mM (7.1 mg/dL; 8%) for each percentage-point decrease in the glycohemoglobin in a randomly selected insulindependent diabetes mellitus population.
11 As in our series, patients with T1D with GH had significantly higher values of HbA 1c than patients with T1D without GH; this could have contributed to higher triglycerides and cholesterol levels. Furthermore, the higher risk of DKA in GH may indicate unique alterations in lipolysis that may account for changes in the lipid tests. Visceral white adipose tissue secretes adipokines that mediate the inflammatory response associated with central obesity and its complications, including nonalcoholic fatty liver disease and steatohepatitis. 12 It is possible that patients with GH have defects in fat biology and adipokines that may mediate the unique metabolic state and cause liver injury similar to nonalcoholic liver disease. However, this needs to be investigated further to better understand the pathophysiologic mechanisms in patients with GH.
This study confirms the association of recurrent DKA with GH. GH could be considered a surrogate marker of poor glycemic control. Fortunately, GH does not lead to adverse long-term outcomes and the liver enzymes eventually normalize in most patients on follow-up. None of the patients had advanced hepatic fibrosis. It is important to note that GH can be seen in young adults with T1D and most patients do not present with the classic Mauriac syndrome features, such as dwarfism and cushingoid features. The presentation of adults is quite similar to that of children except for higher AST and lower albumin levels. The study describes one of the largest single-center series of GH, with a significant proportion of young adult patients.
The limitations of the study are its retrospective nature and the loss to follow-up of nearly 40% of the patients. Also information on some laboratory tests, such as lactose dehydrogenase and glutamate dehydrogenase, was not available in all the patients. Glycogen storage disorders, such as von Gierke disease, may have similar biopsy findings. However, the age of presentation, clinical history of T1D, lack of developmental delay, or severe lactic acidosis made the diagnosis of von Gierke disease unlikely.
In conclusion, patients with T1D with GH frequently had a history of recurrent DKA and elevated HbA 1c levels. Growth retardation was uncommon in GH. Compared with pediatric patients with GH, adult patients had similar clinical imaging and laboratory features, except for higher AST and lower albumin levels. On follow-up, liver enzymes normalized in most patients. 
